Biotech Values

[Rocky3]

Before you answer those questions, how accurate are those estimates? It doesn't seem these estimates match with Olysio revenue reported by JNJ unless JNJ has been discounting Olysio heavily like 50%.

The statement sure surprised me. Script numbers also don't match. The quote from the transcript is:

The genotype distribution of patients that receive treatment is approximately representative of the U.S. HCV population with around 60% usage in genotype 1, 25% in genotype 2, 10% in genotype 3 and 5% in genotypes 4, 5 and 6 combined. We have noticed the reporting of an increased use of the interferon free regimen used in the Phase 2 Cosmos study comprised of Sovaldi with simeprevir and we estimate that during quarter two 70% of Sovaldi usage was in interferon free regimens including Cosmos.

Of course the quote may not be accurate, but you can see how one could interpret the quote as the other poster did.